What is the Best Way to Provide a Phenytoin Load? Edwin Kuffner, MD Rocky Mountain Poison and Drug Center University of Colorado.

Slides:



Advertisements
Similar presentations
First Line Therapy in Acute Seizure Management William C. Dalsey, MD, MBA, FACEP Department of Emergency Medicine Robert Wood Johnson University Hospital.
Advertisements

MANAGING SUBTHERAPEUTIC AED LEVELS Edwin Kuffner, MD, FACEP Rocky Mountain Poison and Drug Center Denver, Colorado.
Managing Seizure Patients in the Emergency Department Managing Seizure Patients in the Emergency Department James Wheless, MD Director, Texas Comprehensive.
J. Stephen Huff, MD, FACEP Critical Issues in the Evaluation and Management of Adult Patients Presenting to the ED with Seizures: The 2004 ACEP Clinical.
Status Epilepticus-Definition
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Issues Surrounding the Management of Patients Who Present to the Emergency Department with Subtherapeutic Phenytoin Levels and a History of Seizures Edwin.
M ONITORING A DVERSE D RUG R EACTIONS (ADR S ) Dr. Dorothy Aywak 1.
Seizures: Nuts and Bolts National Pediatric Nighttime Curriculum Written by Anna Lin, MD Lucile Packard Children’s Hospital.
Epilepsy 2 Dr. Hawar A. Mykhan.
Neurological Emergencies Dr. Amal Alkhotani MBBCH, FRCPC, Epilepsy and EEG.
Seizures: Nuts and Bolts Nightfloat Curriculum Lucile Packard Children’s Hospital Residency Program.
Prepared by: Raed A. AL-Mohiza Directed by: Dr. Hesham Abo-Audah
Pharmacokinetics Questions
MEDICATION SAFETY: Clozapine Initiation Chart Review
Clinical Policy: Critical Issues for the Evaluation and Management of Adult Patients Presenting With Seizures Andy Jagoda, MD, FACEP Professor of Emergency.
Status Epilepticus (SE): Rx Following Benzodiazepine Use Edward Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois.
How Do We Evaluate, Treat, and Disposition New Onset Seizure Patients? Andy Jagoda, MD, FACEP Professor of Emergency Medicine Mount Sinai School of Medicine.
First Line Therapy in Acute Seizure Management William C. Dalsey, MD, FACEP, MBA Department of Emergency Medicine Robert Wood Johnson University Hospital.
Pediatric Prehospital Seizure Management: Evidence Based Guidelines and State of Care in CO Kathleen Adelgais, MD MPH Pediatric Emergency Medicine Children’s.
Principal Investigator
Edward P. Sloan, MD, MPH, FACEP Optimizing ED Seizure & SE Patient Management: A Useful SE Treatment Protocol.
Andy S. Jagoda, MD 1 Seizure and Status Epilepticus Therapeutics: A 2005 Update.
Issues Surrounding the Management of Patients Who Present to the ED with Subtherapeutic Phenytoin Levels and a History of Seizures J. Stephen Huff, MD.
Adult Seizure and SE Patient ED Care: Crossfire Edward P. Sloan, MD, MPH, FACEP 1.
Benzodiazepines What are the Best Non-IV Parenteral Options for a Seizing Patient? William C. Dalsey, MD, FACEP, MBA Department of Emergency Medicine Robert.
Managing and Detecting Seizures in the ICU Special thanks to: Katherine Nickels, MD Assistant Professor of Neurology and Pediatrics Mayo Clinic.
ACEP Clinical Policy: ACEP Clinical Policy: Critical Issues for the Evaluation and Management of Adult Patients Presenting With Seizures William C. Dalsey,
Psychiatric Services in an Emergency Department Prepared by: Kathleen Crapanzano, MD DHH, OMH Medical Director Presented by: Patricia Gonzales, LCSW Acting.
Edward P. Sloan, MD, MPH, FACEP Putting it All Together with Seizure Clinical Policies: Making Good Clinical Decisions & Improving ED Seizure Patient Care.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
J. Stephen Huff, MD 1 What the ACEP Seizure Clinical Policy Doesn’t Tell Us about Adult Seizure and Status Epilepticus Patients… What the ACEP Seizure.
Edward P. Sloan, MD, MPH, FACEP Optimizing Seizure and SE Patient Management: Seizure Therapies Workshop and Clinical Policy Review.
Jason Haag Intern Conference. Case 34 y.o. with h/o seizure disorder presents to ED with increased seizure frequency. He states he’s had 4 tonic-clonic.
INTRAVENOUS INFUSION.
Mosby items and derived items © 2005, 2002 by Mosby, Inc. CHAPTER 13 Antiepileptic Agents.
Background Collection of S & O Information Data: – CC, HPI, PMH, PSHx, Demographics – Medication history including compliance etc. – VS, ROS, Lab, other.
Management. Goals of emergency management for status epilepticus Ensure adequate brain oxygenation and cardiorespiratory function Terminate clinical and.
Conscious Sedation.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 15 Antiepileptic Drugs.
Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.
DVT Prevention and Anticoagulant Management
When is a meta-analysis helpful? EBM: 9/18/2012. Evidence-based medicine 25 year old woman presents with an acute migraine. She doesn’t respond to subcutaneous.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 13 Antiepileptic Drugs.
Status epilepticus the paeds emerg perspective Stephen C. Porter MD MPH MSc Division Chief, Pediatric Emergency Medicine The Hospital for Sick Children.
Multiple dosing: intravenous bolus administration
First Line Therapy in Acute Seizure Management: Focusing on the Pediatric Patient William C. Dalsey, MD, FACEP, MBA Department of Emergency Medicine Robert.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
BIOPHARMACEUTICS.
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Clinical Pharmacokinetic Equations and Calculations
Question Are Medical Emergency Team calls effective in reducing cardiopulmonary arrest rates in the general medical surgical setting? Problem The degree.
ALLIE PUNKE PHARMCOKINETICS. PHENYTOIN THE BASICS What is the volume of distribution: Regular floor patient: L/kg Critically ill patient: 0.8.
Seizure Incidence Associated with Bupropion Dosing Errors Reported to a Local Poison Center William Eggleston, PharmD 1 and Ross W. Sullivan, MD 1,2 1.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Anticonvulsants: Phenytoin
Acetylcysteine for Acetaminophen Poisoning
The Nursing Process and Drug Therapy
Acute Liver and Renal Failure : A rare adverse effect of intravenous amiodarone Robin Paudel1, Saurav Suman1, Prerna Dogra1, Saurav Acharya1, Jyoti Matta1.
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
實證探討Norepinephrine使用周邊靜脈管路輸注之安全性
Anticonvulsants: Valproic acid
Clinical Pharmacokinetics
Pharmcokinetics Allie punke.
Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department  Maria I Rudis, PharmD, Daniel R.
 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.
Principles and Methods of Drug Administration
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

What is the Best Way to Provide a Phenytoin Load? Edwin Kuffner, MD Rocky Mountain Poison and Drug Center University of Colorado

Edwin Kuffner, MD Case Presentation 35 year-old otherwise healthy male presents to the emergency department after having a seizure Past Medical History: seizures since childhood, last seizure 2 years ago Medications: ran out of phenytoin 2 weeks ago Physical Exam: normal vital signs, normal mental status and normal physical exam Serum phenytoin level: undetectable

Edwin Kuffner, MD What is the most effective phenytoin or fosphenytoin dosing strategy for preventing short term seizure recurrence in a patient with a pre-existing seizure disorder who presents to the emergency department within 24 hours of having had a seizure without status epilepticus and who is determined to have a “subtherapeutic” serum phenytoin level?

Edwin Kuffner, MD What common dosing strategy would you use? A.Administer a loading dose of intravenous phenytoin and start/restart daily oral maintenance doses B.Administer a loading dose of intravenous fosphenytoin and start/restart daily oral maintenance doses C.Administer a loading dose of oral phenytoin and start/restart daily oral maintenance doses D.Start/restart daily oral maintenance doses without administering a loading dose

Edwin Kuffner, MD Questions Surrounding This Issue What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, intravenous and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED?

Edwin Kuffner, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? Many patients remain seizure free at levels less than 10 mg/L and some patients require levels greater than 20 mg/L for seizure control. 1 At levels greater than 20 mg/L patients are more likely to have adverse events but many patients will experience adverse events at “therapeutic levels”. 2 1: Carter: Arch Neurol Psych 1958 and Leppick: Adv Neurol : Ambrosetto: Epilepsia 1977 and Product information

Edwin Kuffner, MD Although achieving a “therapeutic” serum phenytoin level between mg/L may be a measure of pharmacokinetic efficacy a more relevant measure of clinical efficacy should be prevention of seizure recurrence with an acceptable adverse effects profile.

Edwin Kuffner, MD By what route of administration can a serum phenytoin level > 10 mg/L be achieved? A level > 10 mg/L can be achieved: –Immediately following an intravenous loading dose 1 –Within 3-10 hours in some cases and within 24 hours in most cases following an oral loading dose 2 –Within 3-7 days following daily maintenance dosing without a loading dose 3 –Within 1-2 hours in most cases and within 24 hours in almost all cases following an intramuscular loading dose 4 1: Carducci, Kugler, Leppick, Salem 2:Osborn, Rantakorn, Record, Wilder 3: Buchanan Gugler Svensmark 4:Boucher, Browne, Kugler, Uthman, Wilder

Edwin Kuffner, MD Regardless of the initial dosing strategy patients require daily maintenance doses to maintain the serum level > 10 mg/L. Less than 20% of adult patients taking 300 mg/day will achieve a serum level > 10 mg/L. 1 1: Buchanan, Gugler

Edwin Kuffner, MD What adverse events are associated with oral, intravenous and intramuscular dosing of phenytoin and fosphenytoin? Irrespective of dosing strategy ataxia, nystagmus and somnolence are common. Following intravenous dosing: Adverse local effects: –phlebitis, purple glove syndrome, tissue necrosis 1 Adverse systemic effects: –impaired myocardial contractility, dysrhythmias, hypotension, cardiac arrest 2 1: Comer, Marchetti, O’Brien, Kilarski 2: Earnst, Russell, York

Edwin Kuffner, MD 1: Boucher, Jameson, Henken Both local and systemic adverse effects are reported much less commonly with fosphenytoin than with intravenous phenytoin. 1 1: Boucher, Jameson, Henken

Edwin Kuffner, MD What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin? In 5/2002 it costs approximately: $95.00 for 1000 mg of fosphenytoin $5.50 for 1000 mg of parenteral phenytoin $5.00 for 1000 mg of oral phenytoin

Edwin Kuffner, MD What is the risk of seizure recurrence in a patient that is discharged from the ED? Data on the risk of seizure recurrence is commonly reported in years not days or weeks. It is difficult to compare studies because: –The background incidence of short term seizure recurrence is unknown. –Most studies included patients with many different etiologies for their seizures. 6-20% is a rough estimate 1 1: Cranford, Huff, Leppick, Osborn

Edwin Kuffner, MD What the Literature Can Tell Us A serum phenytoin level > 10 mg/L can be achieved by all of the common contemporary dosing strategies and by intramuscular fosphenytoin administration. Fewer adverse effects are associated with administration of fosphenytoin than parenteral phenytoin preparations. Fosphenytoin remains considerably more expensive than parenteral phenytoin.

Edwin Kuffner, MD What the Literature Cannot Yet Tell Us The short-term rate of seizure recurrence following emergency department discharge for subsets of patients with different etiologies seizures on different anti-epileptic drugs. Whether there is a difference in the short term rate of seizure recurrence in patients with subtherapeutic serum phenytoin levels treated with any of the common dosing strategies. –No well designed study has been conducted to investigate this important issue

Edwin Kuffner, MD Emergency physicians who understand the pharmacokinetic, pharmacoeconomic and adverse event profiles of phenytoin and fosphenytoin as well as the limitations of the medical literature are best suited to help their patients make informed decisions regarding the different dosing strategies.

Edwin Kuffner, MD Practical Recommendation #1 When I want to achieve a “therapeutic” serum phenytoin level prior to discharge I load with intravenous phenytoin or fosphenytoin. Examples: –Recent history of multiple seizures –History of status epilepticus –Discharge to an environment of questionable safety –Medicolegal concerns

Edwin Kuffner, MD Practical Recommendation #2 When I want to minimize the adverse local and systemic effects associated with IV loading, I administer fosphenytoin. Examples: –Poor intravenous access or small IV catheter –Agitated patient –Limited patient supervision during infusion –Cost is relatively unimportant –Medicolegal concerns

Edwin Kuffner, MD Practical Recommendation #3 When I need to discharge the patient as soon as possible I administer an oral loading dose or fosphenytoin intramuscularly. Examples –Emergency department resources are critical –Unclear indication for phenytoin therapy

Edwin Kuffner, MD Recommendations Class A: None specified. Class B: None specified. Class C: 1.Administer a parenteral loading dose of phenytoin (IV) or fosphenytoin (IV or IM) and restart daily oral maintenance dosing. 2.Administer an oral loading dose of phenytoin and then start/restart daily oral maintenance dosing.